Monitor for potential downward pressure on the stock price due to share dilution from the capital raise, especially given the company's small $21M market cap. The funding provides runway for LYMPHIR commercialization, but investors should watch for execution risks in bringing the product to market.
Price Chart
Executive Summary
Citius Pharmaceuticals entered into a securities purchase agreement to raise $5 million through a registered direct offering of common shares and pre-funded warrants, accompanied by concurrent private placement of warrants. This capital raise, disclosed in an 8-K filing, is intended to fund the commercialization of LYMPHIR and development of other product candidates. The offering was completed within one day of the prior 424B5 filing, confirming immediate execution.
Key Financial Metrics
Key Facts
- Citius Pharmaceuticals raised $5 million through a registered direct offering
- The offering included 4.73 million common shares and pre-funded warrants for 345,686 shares at $0.985 per share
- Concurrent private placement of warrants was also completed
- Net proceeds of $4.5 million will fund LYMPHIR commercialization and other product development
- The offering was completed on April 24, 2026, immediately following the 424B5 filing
Financial Impact
The company raised $5 million in gross proceeds through the issuance of common shares and pre-funded warrants at $0.985 per share, with net proceeds of $4.5 million after expenses
Risk Factors
- Significant share dilution from issuing over 5 million shares and warrants
- Execution risk in commercializing LYMPHIR despite new funding
- Potential downward price pressure from investor selling after the offering
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-047599 |
| Document: ea028762001ex4-3.htm | 0001213900-26-047599 |
| Document: ea028762001ex4-1.htm | 0001213900-26-047599 |
| Document: ea028762001ex4-2.htm | 0001213900-26-047599 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.4582 | awaiting T+60 | — | $0.4030 (−12.05%) |
Aug 5, 2026 11w ago | 8-K | $0.7809 | awaiting T+60 | — | $0.4030 (−48.39%) |
Jun 3, 2026 20w ago | EFFECT | $0.5800 $0.6290 | ▼ −8.45% | ▼ −5.95% | $0.4030 (+30.52%) |
Jun 1, 2026 21w ago | 8-K | $0.6030 $0.5771 | ▼ −4.30% | ▼ −5.41% | $0.4030 (−33.17%) |
May 22, 2026 22w ago | S-3 | $0.6970 $0.6375 | ▲ +8.54% | ▲ +11.26% | $0.4030 (+42.18%) |
May 15, 2026 23w ago | 8-K | $0.5270 $0.7650 | ▼ −45.16% | ▼ −40.31% | $0.4030 (+23.53%) |
Apr 24, 2026 26w ago | 8-K | $0.6910 $0.5623 | ▲ +18.63% | ▲ +23.40% | $0.4030 (+41.68%) |
Apr 24, 2026 26w ago | 424B5 | $0.7700 $0.5455 | ▲ +29.16% | ▲ +34.24% | $0.4030 (+47.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers